Cargando…
E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1
Long noncoding RNAs (lncRNAs) participate in biological processes in multiple types of tumors. However, the regulatory patterns of lncRNAs in prostate cancer remain largely unclear. Here, we evaluated the expression and roles of the lncRNA DLEU2 in prostate cancer. Our results showed that DLEU2 was...
Autores principales: | Li, Peizhang, Xu, Huan, Yang, Liu, Zhan, Ming, Shi, Yuanping, Zhang, Caoxu, Gao, Dajun, Gu, Meng, Chen, Yanbo, Wang, Zhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786838/ https://www.ncbi.nlm.nih.gov/pubmed/35075115 http://dx.doi.org/10.1038/s41419-022-04525-1 |
Ejemplares similares
-
ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner
por: Li, Peizhang, et al.
Publicado: (2022) -
MAFG-AS1 is a prognostic biomarker and facilitates prostate cancer progression
por: Li, Peizhang, et al.
Publicado: (2022) -
Silencing of DLEU2 suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA‐455
por: Xu, Baoli, et al.
Publicado: (2019) -
LncRNA DLEU2 accelerates the tumorigenesis and invasion of non–small cell lung cancer by sponging miR‐30a‐5p
por: Wu, Weiming, et al.
Publicado: (2019) -
Deleted in lymphocytic leukemia 2 (DLEU2): a possible biomarker that holds promise for future diagnosis and treatment of cancer
por: Qu, Xue, et al.
Publicado: (2023)